| scholarly article | Q13442814 |
| P2093 | author name string | M C Cheung | |
| M E Trudeau | |||
| K K W Chan | |||
| A Chambers | |||
| N Penner | |||
| S K Andersen | |||
| P2860 | cites work | Postapproval studies of drugs initially approved by the FDA on the basis of limited evidence: systematic review | Q33647393 |
| Analysis of drug coverage before and after the implementation of Canada's Common Drug Review. | Q35576993 | ||
| Trends in utilization of FDA expedited drug development and approval programs, 1987-2014: cohort study | Q36087521 | ||
| Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada | Q37609850 | ||
| Notice of compliance with conditions: a policy in limbo | Q41892779 | ||
| The characteristics and fulfillment of conditional prescription drug approvals in Canada | Q44337571 | ||
| Accelerated Approval and Expensive Drugs - A Challenging Combination | Q47877826 | ||
| Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. | Q53181590 | ||
| Quality of evidence considered by Health Canada in granting full market authorisation to new drugs with a conditional approval: a retrospective cohort study. | Q53282175 | ||
| New drug, antibiotic, and biological drug product regulations; accelerated approval--FDA. Final rule | Q74762300 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Canada | Q16 |
| Health Canada | Q1057591 | ||
| medical oncology | Q6050805 | ||
| P304 | page(s) | e100-e105 | |
| P577 | publication date | 2019-02-01 | |
| P1433 | published in | Current Oncology | Q3498968 |
| P1476 | title | Conditional approval of cancer drugs in Canada: accountability and impact on public funding | |
| P478 | volume | 26 |
| Q90208028 | Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review | cites work | P2860 |
Search more.